A Single Center, Two Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effect on Vasomotor Symptoms of Q-122 in Female Subjects with Breast Cancer and Receiving an Aromatase Inhibitor or Tamoxifen

Trial Profile

A Single Center, Two Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effect on Vasomotor Symptoms of Q-122 in Female Subjects with Breast Cancer and Receiving an Aromatase Inhibitor or Tamoxifen

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2015

At a glance

  • Drugs Q 122 (Primary)
  • Indications Hot flashes
  • Focus Adverse reactions; Proof of concept
  • Sponsors QUE Oncology
  • Most Recent Events

    • 27 Sep 2015 Results presented at the ASCO - Breast Cancer Symposium 2015
    • 06 Nov 2014 New trial record
    • 03 Nov 2014 Results published in QUE Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top